Gritstone bio Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Gritstone bio'in gelir ve kazançlarının sırasıyla 151.3% ve 2% yıllık düşüş göstermesi beklenirken, EPS'nin büyümesi beklenmektedir.

Anahtar bilgiler

-2.0%

Kazanç büyüme oranı

13.0%

EPS büyüme oranı

Biotechs kazanç büyümesi	42.4%
Gelir büyüme oranı	-151.3%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	30 Oct 2024

Gelecekteki son büyüme güncellemeleri

Güncelleme yok

Recent updates

Kazanç ve Gelir Büyüme Tahminleri

BST:2JQ - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2025	N/A	-133	N/A	N/A	1
12/31/2024	3	-115	N/A	N/A	1
6/30/2024	15	-133	-112	-111	N/A
3/31/2024	16	-145	-118	-115	N/A
12/31/2023	16	-138	-126	-122	N/A
9/30/2023	10	-139	-138	-133	N/A
6/30/2023	12	-130	-133	-127	N/A
3/31/2023	15	-125	-128	-123	N/A
12/31/2022	20	-120	-122	-116	N/A
9/30/2022	19	-118	-115	-109	N/A
6/30/2022	18	-116	-105	-98	N/A
3/31/2022	16	-112	-101	-95	N/A
12/31/2021	48	-75	-56	-51	N/A
9/30/2021	46	-72	-57	-52	N/A
6/30/2021	45	-70	-61	-57	N/A
3/31/2021	42	-71	-58	-55	N/A
12/31/2020	4	-105	-93	-89	N/A
9/30/2020	4	-106	-95	-86	N/A
6/30/2020	4	-107	-105	-91	N/A
3/31/2020	4	-103	-104	-89	N/A
12/31/2019	4	-94	-101	-85	N/A
9/30/2019	5	-84	-88	-76	N/A
6/30/2019	4	-75	-56	-49	N/A
3/31/2019	3	-69	-49	-42	N/A
12/31/2018	1	-65	-44	-38	N/A
9/30/2018	0	-65	-46	-40	N/A
6/30/2018	N/A	-56	-60	-49	N/A
3/31/2018	N/A	-47	N/A	-44	N/A
12/31/2017	N/A	-41	N/A	-35	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: 2JQ önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: 2JQ önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: 2JQ önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: 2JQ şirketinin gelirinin önümüzdeki 3 yıl içinde düşmesi bekleniyor (yılda -151.3% ).

Yüksek Büyüme Geliri: 2JQ şirketinin gelirinin önümüzdeki 3 yıl içinde düşmesi öngörülüyor (yılda -151.3% ).

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: 2JQ 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Gritstone bio Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Recent updates

Gritstone bio, Inc. Announces Encouraging Updated Interim Phase 2 Data from Ongoing Phase 2 Study Evaluating GRANITE

Motion for Asset Sale Filed by Gritstone bio, Inc.

Gritstone bio, Inc.(OTCPK:GRTS.Q) dropped from NASDAQ Composite Index

Gritstone bio Receives Delisting Notice from Nasdaq Due to Chapter 11 Case and it Does Not Intend to Appeal the Determination

New major risk - Market cap size

Gritstone Bio Announces Interim Phase 2 Data for Granite Individualized Neoantigen Targeting Immunotherapy in Frontline Metastatic Microsatellite Stable Colorectal Cancer

Second quarter 2024 earnings released: US$0.16 loss per share (vs US$0.31 loss in 2Q 2023)

Gritstone Bio, Inc. Receives Non-Compliance Notice Regarding Minimum Bid Price Requirement

Gritstone Bio, Inc. Receives Non-Compliance Notice Regarding Minimum Bid Price Requirement

New major risk - Revenue and earnings growth

First quarter 2024 earnings released: US$0.34 loss per share (vs US$0.30 loss in 1Q 2023)

Gritstone bio, Inc. to Report Q1, 2024 Results on May 09, 2024

Gritstone bio, Inc., Annual General Meeting, Jun 17, 2024

Gritstone Bio, Inc. Announces Board Changes

Nature Medicine Publishes Interim Results from Gritstone Bio's Phase 1/2 Study of "Off-The-Shelf" Neoantigen Vaccine Platform (SLATE)

New minor risk - Market cap size

Gritstone bio, Inc. has completed a Follow-on Equity Offering in the amount of $32.5 million.

Gritstone Bio, Inc. Announces Positive Preliminary Progression-Free Survival and Long-Term Circulating Tumor DNA (ctDNA) Data from Phase 2/3 Study of its Personalized Cancer Vaccine, Granite, Granite, Granite

Full year 2023 earnings released: US$1.20 loss per share (vs US$1.32 loss in FY 2022)

Gritstone Bio Announces Update to Comparative Phase 2B Covid-19 Clinical Trial

Gritstone Bio, Inc. Announces Presentation of Results from Three Ongoing Phase 1 Studies Evaluating Its Self-Amplifying Mrna (Samrna) Vaccine Candidates Against Covid-19 (Part of the Company’s Coral Program) at IDWeek 2023

Second quarter 2023 earnings released: US$0.31 loss per share (vs US$0.34 loss in 2Q 2022)

New major risk - Financial position

Gritstone bio, Inc. to Report Q1, 2023 Results on May 11, 2023

Full year 2022 earnings released: US$1.32 loss per share (vs US$0.95 loss in FY 2021)

Gritstone bio, Inc. Announces Updated Overall Survival Results from Granite Phase 1/2 Study and Poster At Sitc 2022

Third quarter 2022 earnings released: US$0.35 loss per share (vs US$0.36 loss in 3Q 2021)

Gritstone bio, Inc. announced that it expects to receive $44.999991 million in funding from Redmile Group, LLC, Gilead Sciences, Inc., The Invus Group, LLC, Hercules Capital, Inc. and other investors

Gritstone bio, Inc. Presents Positive Initial Phase 2 Data in Late-Line Solid Tumor Patients Treated with KRAS-Directed Immunotherapy at ESMO 2022

Gritstone bio, Inc. Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of GRANITE, Individualized Neoantigen Vaccine for Solid Tumors

Gritstone Appoints Dr. Lawrence “Larry” Corey to Its Board of Directors, Effective from August 12, 2022

Second quarter 2022 earnings released: US$0.34 loss per share (vs US$0.33 loss in 2Q 2021)

Gritstone bio, Inc.(NasdaqGS:GRTS) dropped from Russell 2500 Index

Gritstone Announces Results from Preclinical Study of Its Self-Amplifying Mrna (Samrna) Vaccine Against Sars-Cov-2 Published in Nature Communications

Gritstone Bio, Inc. Announces Updated Overall Survival Results in Advanced Colorectal Cancer Patients from Phase 1/2 Study of Granite and Trial in Progress Poster At Asco

First quarter 2022 earnings released: US$0.33 loss per share (vs US$0.16 profit in 1Q 2021)

Gritstone bio, Inc. to Report Q1, 2022 Results on May 05, 2022

Less than half of directors are independent

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Less than half of directors are independent

Gritstone Announces First Patient Enrolled for Phase 2/3 Trial Evaluating Individualized Neoantigen Vaccine GRANITE for First Line (1L) Maintenance Treatment of Metastatic, Microsatellite-Stable Colorectal Cancer (MSS-CRC)

Less than half of directors are independent

Gritstone Bio, Inc. Announces Positive Clinical Results from First Cohort of A Phase 1 Study (CORAL-BOOST) Evaluating A T Cell-Enhanced Self-Amplifying mRNA (SamRNA) Vaccine Against COVID-19

Gritstone bio, Inc Announces Omicron Variant of SARS-CoV-2 has Minimal Impact on the T Cell Epitopes (Targets) Contained within Gritstone’s Self-Amplifying mRNA COVID-19 Vaccines

Gritstone Announces Dosing of First Volunteer in Trial Evaluating Self-Amplifying mRNA as a COVID-19 Vaccine Booster and Immunogenicity Enhancer

Gritstone Bio, Inc. Announces Dosing of First Solid Tumor Patient with Optimized SLATE “Off-the-Shelf” Mutant KRAS-directed Neoantigen Immunotherapy in Phase 2 Clinical Trial

Gritstone to Host Data Update on Neoantigen Oncology Programs for the Treatment of Solid Tumors During ESMO 2021

Second quarter 2021 earnings released: US$0.33 loss per share (vs US$0.69 loss in 2Q 2020)

High number of new directors

Gritstone bio, Inc.(NasdaqGS:GRTS) dropped from Russell 2500 Growth Index

First quarter 2021 earnings released: EPS US$0.10 (vs US$0.71 loss in 1Q 2020)

Full year 2020 earnings released: US$2.79 loss per share (vs US$2.81 loss in FY 2019)

Revenue beats expectations

Gritstone Oncology, Inc. Announces Promotions Within its Leadership Team

Gritstone Oncology, Inc Announces Board Appointments

Executive VP & CTO recently sold €182k worth of stock

Gritstone Oncology, Inc. and Genevant Sciences Announce License Agreement for COVID-19 Vaccine

Gritstone Oncology, Inc. Advances Development of Second Generation Vaccine Against SARS-CoV-2

New 90-day high: €4.70

Gritstone Oncology, Inc. announced that it expects to receive $15.000001 million in funding

New 90-day high: €3.34

Gritstone Oncology, Inc. announced that it expects to receive $110 million in funding from Avidity Partners Management LP, EcoR1 Capital, LLC, Redmile Group, LLC, and other investors

Gritstone Oncology, Inc Announces Resignation of Jean-Marc Bellemin as Chief Financial Officer

New 90-day low: €2.16

Third quarter 2020 earnings released: US$0.69 loss per share

Revenue misses expectations

Gritstone Oncology, Inc. Advances into Phase 2 Expansion Cohorts for its Personalized Neoantigen Immunotherapy GRANITE and its Off-the-Shelf Neoantigen Immunotherapy SLATE

New 90-day low: €2.32

Gritstone Oncology, Inc.(NasdaqGS:GRTS) dropped from S&P Global BMI Index

New 90-day low - €2.72

First half earnings released

New 90-day low - €2.76

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri